AstraZeneca's Drug Pipeline Outside Oncology Seems Underrated -- Market Talk

Dow Jones14:07

0606 GMT - AstraZeneca has released promising data for pipeline drugs outside its core oncology business that seem underrated by the market, Bernstein analysts say in a research note. Non-oncology drugs account for nearly two-thirds of Bernstein's estimate for the U.K. pharmaceutical company's sales growth over the next five years, the analysts say. Upcoming data for AstraZeneca's Wainua drug in a trial for transthyretin amyloid cardiomyopathy--a heart disease--and for experimental cholesterol treatment AZD0780 could be key, the analysts add. The company estimates annual peak sales for each drug to top $5 billion and Bernstein says the targets are credible. Moreover, a recent late-stage study of its tozorakimab drug candidate for smokers' cough seems to vindicate AstraZeneca's approach of developing potentially the best--rather than first--of its class of medicines, Bernstein notes. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 05, 2026 02:07 ET (06:07 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment